Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Operating metrics disclosed this quarter
Read from the filing itself — XBRL does not carry these, so no standard financial dataset has them.
Patient Service Equipment Capital Expenditures
$-43,796
Three Months Ended June 30, (Dollars in thousands) 2026 2025 Patient service equipment capital expenditures (43,796) (57,260)
Free Cash Flow
$-25,103
The following financial measures, Adjusted EBITDA and Free Cash Flow (FCF), are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). We use Adjusted EBITDA, a financial measure that is not in accordance with GAAP, to analyze our financial results and as one of our incentive metrics and to provide an understanding of underlying operating results and trends by excluding items that are not closely related to ongoing operations. We use FCF, a financial measure that is not in accordance with GAAP, to evaluate the capacity of our operations to generate free cash flow. We utilize FCF as a performance metric. Three Months Ended June 30, (Dollars in thousands) 2026 2025 Free cash flow (non-GAAP) $ (25,103) $ 15,169
Adjusted EBITDA
$60,089
The following financial measures, Adjusted EBITDA and Free Cash Flow (FCF), are not calculated in accordance with U.S. generally accepted accounting principles (GAAP). We use Adjusted EBITDA, a financial measure that is not in accordance with GAAP, to analyze our financial results and as one of our incentive metrics and to provide an understanding of underlying operating results and trends by excluding items that are not closely related to ongoing operations. We use FCF, a financial measure that is not in accordance with GAAP, to evaluate the capacity of our operations to generate free cash flow. We utilize FCF as a performance metric. Three Months Ended June 30, (Dollars in thousands) 2026 2025 Adjusted EBITDA (non-GAAP) 60,089 96,635
Days Sales Outstanding
17.8
Financial condition . We monitor operating working capital through days sales outstanding (DSO). June 30, 2026 December 31, 2025 DSO (1) 17.8 12.4 (1) Based on period end accounts receivable, net and net revenue for the quarters ended June 30, 2026 and December 31, 2025. Excluding the impact of the Amended Receivables Sale Program, DSO would have been 37.1 and 29.8 as of June 30, 2026 and December 31, 2025.
Days Sales Outstanding excluding Receivables Sale Program
37.1
Financial condition . We monitor operating working capital through days sales outstanding (DSO). June 30, 2026 December 31, 2025 DSO (1) 17.8 12.4 (1) Based on period end accounts receivable, net and net revenue for the quarters ended June 30, 2026 and December 31, 2025. Excluding the impact of the Amended Receivables Sale Program, DSO would have been 37.1 and 29.8 as of June 30, 2026 and December 31, 2025.